NASDAQ OMX

LifeSci Advisors Announces 10th Board Appointment Through Board Placement Initiative

Dela

Dr. Kristine Swiderek Appointed to the Board of Directors of Sitka Biopharma Inc.

NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) --  LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today the 10th placement of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI). LifeSci Advisors launched BPI last year with the goal of connecting female executives in the life sciences industry with companies looking for board candidates. The company is pleased to share that Dr. Kristine Swiderek, Co-founder and Chief Scientific Officer of OncoResponse, has joined the Board of Directors of Sitka Biopharma Inc., a Canadian biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Dr. Swiderek's placement marks a milestone for BPI as the 10th successful appointment made by the program in just one year. LifeSci Advisors will continue to make connections and look to match more candidates in the coming months.

"I am honored to serve on the Board of Directors of Sitka Biopharma," said Dr. Swiderek. "I look forward to helping the company as it works to advance products in the industry and improve the lives of patients. I would like to thank LifeSci Advisors for facilitating this introduction and the work the Board Placement Initiative is doing to place talented, qualified women on the boards of companies in the life sciences industry."

Dr. Swiderek is the Co-founder and Chief Scientific Officer of venture backed OncoResponse, a company focusing in immuno-oncology, discovering and developing novel cancer Immunotherapies. She brings deep expertise in clinical, R&D, partnering and alliance management to Sitka's Board. Previously as CSO at Theraclone Sciences, she formed multiple R&D partnerships with Pfizer, Gilead, non-profit organizations and academia and helped advance therapeutic candidates into the clinic. She also served as Vice President, Protein Science at ZymoGenetics, a public company, where she managed extensive internal and external partner portfolios. As Senior Director in Protein Biochemistry, she helped develop the PEG-Interferon lambda program, which ultimately was a cornerstone for a $1.1B partnership with Bristol-Myers Squibb. Dr. Swiderek did her post-doctoral training at the City of Hope, CA, and Indiana University following a Ph.D. at Ruhr-Universität Bochum, Germany. Dr. Swiderek is currently based in Seattle, WA.

"Dr. Swiderek's experience will be an incredible asset to the Sitka Board of Directors," said Michael Rice, President and Co-Founder, LifeSci Advisors. "We are thrilled that LifeSci Advisors' Board Placement Initiative has been able to play a role in facilitating this appointment and excited to mark this milestone of our 10th board placement in just one year. Our program is designed to support women in our industry and make the life sciences a more diverse and inclusive space. We look forward to continuing to successfully match candidates with companies across the industry and hope to see more placements in the coming months."

"We are pleased to welcome Dr. Swiderek to the Sitka Biopharma Board," said Dr. Michael Parr, President and Chief Scientific Officer, Sitka Biopharma. "Her energy and expertise in clinical development will prove invaluable as we continue to advance our leading product toward the clinic, and ultimately improve the lives of patients living with bladder cancer. I'd like to thank LifeSci Advisors for making an introduction to such a great board director." 

LifeSci Advisors' Board Placement Initiative (BPI) was launched in the summer of 2016 with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Connections between companies and eligible board candidates are made after LifeSci has met with a company's management team or board regarding the skills and expertise they are looking for in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI has now helped to place ten women on corporate boards, and is looking to continue to expand upon this success. With a proprietary online network of hundreds of resumes of board-ready women, LifeSci Advisors hopes that BPI can become a resource for both women executives and life sciences companies to network and grow.

BPI is accepting resumes from interested candidates and referrals on an ongoing basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to boarddiversity@lifesciadvisors.com.

LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategies, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows us to provide a valuable and unique service offering to our clients.

LifeSci Partners (www.lifescipartners.com) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory.  Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally.  LifeSci Partners has a physical presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv.

For further information, please contact:

Ann Kaiser                                                                                          
The TASC Group
212-337-8870
ann@thetascgroup.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Canada's CoinField cryptocurrency exchange going international with commission-free trading app moonGO through a new partnership23.7.2018 11:30Pressmeddelande

moonGO(TM) app is the fastest and most reliable way to buy/sell and store cryptocurrencies. The app allows users to convert cryptos directly to EUR/USD to be loaded into their moonGo(TM) card and be used anywhere worldwide whether they're shopping online or spending it at a physical retailer who accepts credit cards. VANCOUVER, British Columbia, July 23, 2018 (GLOBE NEWSWIRE) -- CoinField, the most advanced cryptocurrency exchange in Canada is now extending its services worldwide thanks to a new partnership with Malta's Manticore Ventures to create moonGO(TM), a powerful app designed for traders who thrive on agility, flexibility and security. With moonGO(TM), users can set up their trading accounts in about 60 seconds, withdraw fiat currency as Euro or US dollars in the form of moonGO(TM) cards, and use the moonGO(TM) cards to make purchases online or at any retailer that accepts credit cards. The moonGO(TM) app will take CoinField's sterling reputation outside of Canada and make its

UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance23.7.2018 09:00Pressmeddelande

BASHH aiming to raise awareness of Mgen and curb rising antibiotic resistance LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted for consultation on July 8th, 20181[link]. The guideline recommends Resistance Guided Therapy as best practice when treating an Mgen infection, with a strong recommendation for diagnostic tests to direct appropriate antibiotic treatment. Mgen is highly resistant to antibiotics, up to 50% of infections are already resistant to the first-line treatment, azithromycin.2,3 This rate may rise if infections are treated without knowledge of resistance status. The success of Resistance Guided Therapy as treatment for Mgen was published in Clinical Infectious Diseases, June 20182 [link].Cure rates increased from under 68% to over 92% by switching the first-line drug and using the SpeeDx Resistance Plus® MG* test to triage pati

LeoVegas AB: Inbjudan till presentation av LeoVegas delårsrapport för andra kvartalet 201823.7.2018 08:00Pressmeddelande

LeoVegas delårsrapport för det andra kvartalet för 2018 kommer att publiceras klockan 08:00 den 1:a augusti 2018. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och medgrundare samt Viktor Fritzén, CFO, presenterar resultatet. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/zupwii5n För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Bekräftelse kod: 5362090 Webbsändningen, som även kan ses i efterhand, och presentationsmaterialet kommer att finnas tillgängligt på LeoVegas webbplats www.leovegasgroup.com under Investor Relations. För ytterligare information, vänligen kontakta: Gustaf Hagman, Group CEO och medgrundare: +46 (0) 8 410 367 66, gustaf.hagman@leovegas.com Philip Doftvik, Head of Investor

LeoVegas AB: Invitation to presentation of LeoVegas second quarter 201823.7.2018 08:00Pressmeddelande

LeoVegas interim report for the second quarter for 2018 will be published at 08:00 CET on August 1, 2018. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and Co-founder, and Viktor Fritzén, CFO, will present the results. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/zupwii5n To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Confirmation code: 5362090 The webcast, which afterwards also will be available on demand, and presentation material will be published on LeoVegas website, www.leovegasgroup.com under Investor Relations. For further information, please contact: Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, gustaf.hagman@leovegas.com Philip Doftvik, Head of Investor Relations and corporate finance: +46 73 512 0

Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41Pressmeddelande

TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of

eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30Pressmeddelande

SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum